Incyte (INCY) R&D head sells 10,801 shares, holds 183,200 in awards

Rhea-AI Filing Summary

INCYTE CORP (INCY) reported that officer Pablo J. Cagnoni, President, Global Head of R&D, sold 10,801 shares of common stock on 2026-08-19 in an open-market transaction at $125.56 per share, pursuant to a Rule 10b5-1 trading plan. Following this sale, he holds rights to 183,200 shares of common stock issuable from previously reported restricted stock units and earned performance stock units that have not yet vested.

Insider Trade Summary 10b5-1

Net Seller: 10,801 shares

Net Sell 1 txn

Insider CAGNONI PABLO J

Role President, Global Head of R&D

Sold 10,801 shs ($1.36M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	10,801	$125.56	$1.36M

Holdings After Transaction: Common Stock — 183,200 shares (Direct)

Footnotes (1)

1. F1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Key Figures

Shares sold: 10,801 shares of Common Stock Sale price per share: $125.56 per share Post-transaction equity from awards: 183,200 shares of Common Stock +1 more

4 metrics

Shares sold 10,801 shares of Common Stock Non-derivative sale on 2026-08-19

Sale price per share $125.56 per share Open-market or private transaction on 2026-08-19

Post-transaction equity from awards 183,200 shares of Common Stock Issuable from previously reported unvested RSUs and earned PSUs following the transaction

Net shares sold 10,801 shares Net buy/sell shares for this Form 4

Key Terms

Rule 10b5-1 trading plan, restricted stock units, performance stock units

3 terms

Rule 10b5-1 trading plan regulatory

"the transaction was made under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"shares of common stock issuable pursuant to previously reported restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance stock units financial

"issuable pursuant to previously reported restricted stock units and earned performance stock units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

FAQ

What insider transaction did INCY report for Pablo J. Cagnoni?

INCYTE CORP reported that Pablo J. Cagnoni sold 10,801 shares of INCY common stock on 2026-08-19 in an open-market transaction at $125.56 per share, under a Rule 10b5-1 trading plan.

How many INCY shares did Pablo J. Cagnoni sell and at what price?

Pablo J. Cagnoni sold 10,801 shares of INCYTE CORP common stock at a price of $125.56 per share in a reported open-market transaction.

What is Pablo J. Cagnoni’s remaining INCY equity exposure after this Form 4 sale?

After the sale, Pablo J. Cagnoni has rights to 183,200 shares of INCYTE CORP common stock issuable from previously reported restricted stock units and earned performance stock units that have not vested.

Was the INCY insider sale by Pablo J. Cagnoni under a Rule 10b5-1 plan?

Yes. The filing indicates the transaction was made under a Rule 10b5-1 trading plan, meaning the sale followed a pre-arranged trading schedule.

What role does Pablo J. Cagnoni hold at INCYTE CORP (INCY)?

Pablo J. Cagnoni is reported as an officer of INCYTE CORP with the title President, Global Head of R&D at the time of the Form 4 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 05:16 PM Accepted by SEC EDGAR 08/20/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAGNONI PABLO J

(Last) (First) (Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON DELAWARE 19803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Global Head of R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		S		10,801	D	$125.56	183,200(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)